Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner

Texto completo
Autor(es):
Roffe, Martin [1] ; Lupinacci, Fernancla C. [1] ; Soares, Luana C. [1] ; Hajj, Glaucia N. [1] ; Martins, Vilma R. [1]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Int Res Ctr, AC Camargo Canc Ctr, Brazil Natl Inst Sci & Technol Oncogen INCITO, Sao Paulo, SP - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo Científico
Fonte: CELLULAR SIGNALLING; v. 27, n. 8, p. 1630-1642, AUG 2015.
Citações Web of Science: 11
Resumo

The 90 kDa ribosomal S6 kinases (RSK) are effectors of the Ras-ERK1/2 signaling pathway. RSK signaling controls proliferation and protein synthesis, and is altered in several types of tumors. BI-D1870 and SL0101 are two widely used inhibitors of RSK. After revision of the literature, discrepancies in the effects of the inhibitors were identified. Herein we report that while SL0101 inhibited mTORC1-p70S6K signaling, BI-D1870 increased p70S6K activation. Both effects were independent of ERK1/2 and RSK, and thus nonspecific. We also demonstrated how these opposite nonspecific effects mislead the identification of the RSK-dependent phosphorylation of rpS6 (S235/236), a known RSK and p70S6K substrate. Phosphorylation of tuberin at S1798 by RSK was proposed to mediate ERK1/2-dependent activation of mTORC1-p70S6K signaling. In glioblastoma-derived cells, phosphorylation of tuberin was abolished after RSK depletion or ERK1/2 inhibition, suggesting that RSK is its main kinase. However, RSK depletion did not reduce PMA-dependent p70S6K phosphorylation, which suggests that tuberin phosphorylation at S1798 is not the main mediator of ERK1/2-dependent activation of mTORC1. Remarkably, tuberin phosphorylation (S1798) followed the activation status of RSK in different cells and experimental conditions, suggesting that phosphorylation of that residue could be used as readout for RSK activation in cells. We confirmed the difference in the effects of SL0101 and BI-D1870 in cellular proliferation assays. Rapamycin potentiated the inhibition of proliferation induced by BI-D1870, but not by SL0101. We thus conclude that SL0101 and BI-D1870 induce distinct off-target effects in mTORC1-p70S6K signaling, and thus, the functions previously ascribed to RSK based on these inhibitors should be reassessed. (C) 2015 Elsevier Inc All rights reserved. (AU)

Processo FAPESP: 13/25025-6 - Papel de mTOR e RSK no processo de tumorigênese em gliomas
Beneficiário:Luana Campos Soares
Linha de fomento: Bolsas no Brasil - Mestrado
Processo FAPESP: 13/03315-2 - Translatômica aplicada ao descobrimento de alterações moleculares em gliomas
Beneficiário:Fernanda Cristina Sulla Lupinacci
Linha de fomento: Bolsas no Brasil - Doutorado Direto
Processo FAPESP: 09/14027-2 - Mecanismos associados à função da proteína prion e seu ligante STI1/Hop: abordagens terapêuticas
Beneficiário:Vilma Regina Martins
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 11/21350-4 - Regulação da síntese de proteínas através da SUMOilação
Beneficiário:Martín Roffé
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 12/04370-4 - O controle da tradução no sistema nervoso: mecanismos tumorais
Beneficiário:Glaucia Noeli Maroso Hajj
Linha de fomento: Auxílio à Pesquisa - Regular